Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

MithraGen

2000 FOUNDED
M&A STATUS
M&A LATEST DEAL TYPE
Description

Developer of immunotherapies for T and B cells for the treatment and prevention of cancers and infectious diseases. The company develops immunotherapies incorporating Class I and II restricted epitopes for the treatment of cancers and infectious diseases that currently have no satisfactory therapy.

Formerly Known As
MithraTech
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Primary Office
  • 8030 El Rio
  • Houston, TX 77054
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore MithraGen’s full profile, request a free trial.

MithraGen Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 01-Jan-2008 00.000 Completed Generating Revenue
3. Early Stage VC (Series B) 12-Mar-2004 00.00 00.000 00.000 Completed Startup
2. Early Stage VC (Series A) $1.89M $1.89M 00.00 Completed
1. Accelerator/Incubator Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

MithraGen Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series B 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 000,000 00.000000 00.00 00 00 00 00 00.000
To view this company’s complete Cap Table, request access »

MithraGen Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
BCM Technologies Venture Capital Minority 000 0000 000000 0
Emerging Technology Partners Venture Capital Minority 000 0000 000000 0
Wake Forest Baptist Medical Center Corporation 000 0000 000000 0

MithraGen Executive Team (3)

Name Title Board
Seat
Contact
Info
David Anderson Boar Member, Chief Executive Officer & President
J. Payne Chief Financial Officer
Si-Yi Chen Ph.D Scientific Founder & Director